MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 585253 | Name: Triazinate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Triazinate is an anti-tumor compound.

Chemical Structure

Triazinate
Triazinate
CAS#41191-04-2

Theoretical Analysis

MedKoo Cat#: 585253

Name: Triazinate

CAS#: 41191-04-2

Chemical Formula: C23H30ClN6O5S

Exact Mass: 537.1687

Molecular Weight: 538.04

Elemental Analysis: C, 51.34; H, 5.62; Cl, 6.59; N, 15.62; O, 14.87; S, 5.96

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Triazinate; TZT
IUPAC/Chemical Name
3-[[2-chloro-4-(4,6-diamino-2,2-dimethyl-1,3,5-triazin-1-yl)phenoxy]methyl]-N,N-dimethylbenzamide;ethanesulfonic acid
InChi Key
IROWRJNCUILBPD-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H30ClN6O5S/c1-23(2)28-21(25)27-22(26)29(23)17-8-9-19(18(24)13-17)35-14-15-6-5-7-16(12-15)20(31)30(3,4)10-11-36(32,33)34/h5-9,12-13H,10-11,14H2,1-4H3,(H,32,33,34)(H4,25,26,27,28)
SMILES Code
O=C([N](C)(C)CCS(=O)(O)=O)C1=CC=CC(COC2=CC=C(N3C(C)(C)N=C(N)N=C3N)C=C2Cl)=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 538.04 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kalghatgi KK, Moroson BA, Horváth C, Bertino JR. Enhancement of antitumor activity of 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine and Baker's antifol (triazinate) with carboxypeptidase G1. Cancer Res. 1979 Sep;39(9):3441-5. PubMed PMID: 476673. 2: Gralla EJ, Coleman GL, Osbaldiston W, Sawicki WL, Jonas RM, Bertino JR. Preclinical studies with triazinate (NSC-139105), an antifolate drug, in beagle dogs and rhesus monkeys. Cancer Chemother Rep. 1975 May-Jun;59(3):523-30. PubMed PMID: 812604. 3: Greenspan AH, Shupack JL, Foo SH, Wise AC. Acanthosis nigricans-like hyperpigmentation secondary to triazinate therapy. Arch Dermatol. 1985 Feb;121(2):232-5. PubMed PMID: 3977338. 4: Skeel RT, Cashmore AR, Sawicki WL, Bertino JR. Clinical and pharmacological evaluation of triazinate in humans. Cancer Res. 1976 Jan;36(1):48-54. PubMed PMID: 1248009. 5: Skeel RT, Sawicki WL, Cashmore AR, Bertino JR. Inhibition of DNA synthesis in normal and malignant human cells by triazinate (Baker's antifol) and methotrexate. Cancer Res. 1976 Oct;36(10):3659-64. PubMed PMID: 953990. 6: O'Connell MJ, Schutt AJ, Moertel CG, Rubin J, Hahn RG, Scott M. A randomized clinical trial of combination chemotherapy in advanced colorectal cancer. Am J Clin Oncol. 1987 Aug;10(4):320-4. PubMed PMID: 3303905. 7: Chello PL, McQueen CA, DeAngelis LM, Bertino JR. Elevation of dihydrofolate reductase, thymidylate synthetase, and thymidine kinase in cultured mammalian cells after exposure to folate antagonists. Cancer Res. 1976 Jul;36(7 PT 1):2442-9. PubMed PMID: 1277151. 8: Camerman A, Smith HW, Camerman N. Stereochemistry of dihydrofolate reductase inhibitor antitumor agents: molecular structure of "Baker's antifol" (NSC 139105, triazinate) and "insoluble Baker's antifol" (NSC 113423). Biochem Biophys Res Commun. 1978 Jul 14;83(1):87-93. PubMed PMID: 697826. 9: Townsend JG, Jain RK, Cashmore AR. In vivo pharmacokinetics of triazinate in L-1210 and W-256 cells. J Pharm Sci. 1982 Oct;71(10):1102-5. PubMed PMID: 7143204. 10: O'Connell MJ, Schutt AJ, Moertel CG, Hahn RG. Phase II clinical trial of triazinate in combination with mitomycin C for patients with advanced gastric cancer. J Clin Oncol. 1987 Jan;5(1):83-5. PubMed PMID: 3100727. 11: Triazinate and platinum efficacy in combination with 5-fluorouracil and doxorubicin: results of a three-arm randomized trial in metastatic gastric cancer. Gastrointestinal Tumor Study Group. J Natl Cancer Inst. 1988 Sep 7;80(13):1011-5. PubMed PMID: 2900901. 12: Mini E, Moroson BA, Franco CT, Bertino JR. Cytotoxic effects of folate antagonists against methotrexate-resistant human leukemic lymphoblast CCRF-CEM cell lines. Cancer Res. 1985 Jan;45(1):325-30. PubMed PMID: 3855284. 13: Arseneau JC, Bundy B, Dolan T, Homesley H, DiSaia PJ. Phase II study of Baker's antifol (triazinate, TZT, NSC-139,105) in advanced squamous cell carcinoma of cervix. Am J Clin Oncol. 1982 Feb;5(1):61-4. PubMed PMID: 6211087. 14: Nichols WC, Kvols LK, Ingle JN, Edmonson JH, Ahmann DL, Rubin J, O'Connell MJ. Phase II study of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy. Cancer Treat Rep. 1978 May;62(5):837-9. PubMed PMID: 657166. 15: McCreary RH, Moertel CG, Schutt AJ, O'Connell MJ, Hahn RG, Reitemeier RJ, Rubin J, Frytak S. A phase II study of triazinate (NSC 139105) in advanced colorectal carcinoma. Cancer. 1977 Jul;40(1):9-13. PubMed PMID: 141977. 16: Eagan RT, Frytak S, Ingle JN, Creagan ET, Nichols WC, Kvols LK. Phase II evaluation of the combination of triazinate, cyclophosphamide, doxorubicin, and cis-diamminedichloroplatinum(II) in patients with advanced adenocarcinoma of the lung. Cancer Treat Rep. 1980 Aug-Sep;64(8-9):925-8. PubMed PMID: 7192602. 17: Arseneau JC, Bundy B, Homesley H, Beecham J. Phase II study of Baker's antifol (triazinate, TZT, NSC 139, 105) in advanced carcinoma of the ovary. A Gynecologic Oncology Group study. Invest New Drugs. 1983;1(2):185-8. PubMed PMID: 6236163. 18: Vogl SE, Qazi R, Berenzweig M. Combination chemotherapy for advanced colorectal cancer with triazinate, ICRF-159, 5-FU, and methyl-CCNU. Cancer Treat Rep. 1980 Oct-Nov;64(10-11):1143-5. PubMed PMID: 7459902. 19: Hahn RG, Begg CB, Davis T. Phase II study of vinblastine-CCNU, triazinate, and dactinomycin in advanced renal cell cancer. Cancer Treat Rep. 1981 Jul-Aug;65(7-8):711-13. PubMed PMID: 7018680. 20: Tadokoro M, Ohata Y, Ohhata Y, Shimazaki Y, Ishimaru S, Yamada T, Nagao Y, Sugaya T, Isoda K, Suzuki Y, Kitagawa H, Matsui H. Anomalous enhancement of proton conductivity for water molecular clusters stabilized in interstitial spaces of porous molecular crystals. Chemistry. 2014 Oct 13;20(42):13698-709. doi: 10.1002/chem.201402900. Epub 2014 Sep 3. Erratum in: Chemistry. 2019 May 10;25(27):6847. Ohhata Y [corrected to Ohata Y]. PubMed PMID: 25186220.